Citadel Advisors
FBRX

Citadel Advisors’s Forte Biosciences FBRX Stock Holding History

Citadel Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-124
Closed -$1.67K – 14497
2024
Q2 		$1.67K Buy
124
+84
+210% +$1.36K ﹤0.01% 13791
2024
Q1 		$701 Sell
40
-428
-91% -$7.47K ﹤0.01% 14267
2023
Q4 		$9.61K Sell
468
-720
-61% -$10.1K ﹤0.01% 13143
2023
Q3 		$19.7K Buy
1,188
+488
+70% +$10.8K ﹤0.01% 12641
2023
Q2 		$18.2K Sell
700
-56
-7% -$1.46K ﹤0.01% 12814
2023
Q1 		$19.1K Sell
756
-1,792
-70% -$45.1K ﹤0.01% 13100
2022
Q4 		$63.7K Buy
2,548
+720
+39% +$18.5K ﹤0.01% 11836
2022
Q3 		$49K Sell
1,828
-332
-15% -$10.5K ﹤0.01% 11645
2022
Q2 		$70K Buy
2,160
+1,236
+134% +$39.3K ﹤0.01% 11706
2022
Q1 		$34K Sell
924
-2,384
-72% -$90.2K ﹤0.01% 13034
2021
Q4 		$177K Sell
3,308
-4,692
-59% -$316K ﹤0.01% 12035
2021
Q3 		$592K Buy
+8,000
New +$4.43M ﹤0.01% 9453
2020
Q2 		– Sell
-32
Closed -$15K – 9982
2020
Q1 		$15K Buy
+32
New +$12.5K ﹤0.01% 9358
2019
Q4 		– Sell
-677
Closed -$168K – 9290
2019
Q3 		$168K Buy
677
+614
+975% +$932K ﹤0.01% 8243
2019
Q2 		$158K Sell
63
-83
-57% -$246K ﹤0.01% 8329
2019
Q1 		$597K Buy
+146
New +$564K ﹤0.01% 6490

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors's FBRX Position: Q2 2026 in Review

Citadel Advisors increased its Forte Biosciences (FBRX) stake by 135% in Q2 2026, buying an estimated $7.45M and bringing the position to 547,415 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3339.

Citadel Advisors first reported a position in FBRX in Q3 2018 and has held it in 22 quarters since. The position peaked at $16.5M in Q3 2020. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Citadel Advisors held 547,415 shares of Forte Biosciences worth $11.6M as of Q2 2026.
  • Citadel Advisors bought 314,046 Forte Biosciences shares in Q2 2026, an estimated $7.45M.
  • Forte Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3339 holding.
  • Citadel Advisors first reported a position in Forte Biosciences in Q3 2018 and has held it in 22 quarters since.
  • Citadel Advisors's Forte Biosciences position peaked at $16.5M in Q3 2020.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.